Fact-checked by Grok 2 weeks ago

CD1

CD1 is a family of non-polymorphic glycoproteins that serve as antigen-presenting molecules in the mammalian immune system, uniquely specialized for binding and displaying lipid and glycolipid antigens—such as those from microbial pathogens or self-lipids—to T lymphocytes, thereby complementing the peptide-focused presentation by major histocompatibility complex (MHC) class I and II proteins.^[1] Unlike classical MHC molecules, CD1 proteins are evolutionarily conserved across mammals and primarily recognize amphipathic lipids through hydrophobic interactions in their antigen-binding grooves.^[2] This lipid presentation pathway enables the activation of specialized T cell subsets, including natural killer T (NKT) cells, which play critical roles in innate-like and adaptive immune responses.^[1] Structurally, CD1 molecules resemble MHC class I proteins, consisting of a transmembrane heavy chain with three extracellular α-domains (α1, α2, and α3) non-covalently associated with the invariant light chain β₂-microglobulin (β₂m).^[3] The α1 and α2 domains form a hydrophilic platform and two (or more) hydrophobic pockets—designated A′ and F′ in most isoforms, with additional C′ and T′ pockets in CD1b—for accommodating the alkyl chains and polar heads of lipids, respectively.^[2] In humans, the CD1 family comprises five isoforms (CD1a, CD1b, CD1c, CD1d, and CD1e), divided into three groups: group 1 (CD1a–c) for diverse lipid antigens, group 2 (CD1d) for invariant NKT cell ligands, and group 3 (CD1e) as a lipid chaperone without direct presentation.^[1] These isoforms exhibit distinct subcellular trafficking: for instance, CD1a recycles via early endosomes, while CD1b accesses lysosomes for loading complex microbial lipids like mycolic acids from Mycobacterium tuberculosis.^[2] CD1 molecules are predominantly expressed on professional antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages, as well as on epithelial and other non-professional cells in mucosal tissues including the skin, lungs, and intestines, where they survey for lipid threats at barrier sites.^[1] Functionally, CD1a–d isoforms load antigens during biosynthesis in the endoplasmic reticulum (ER) or in endolysosomal compartments, often aided by lipid transfer proteins like saposins or microsomal triglyceride transfer protein (MTP), before trafficking to the cell surface for recognition by CD1-restricted T cells.^[2] This process activates effector functions such as cytokine production (e.g., IFN-γ from type I NKT cells or IL-4 from type II NKT cells) and cytotoxicity, contributing to antimicrobial defense, tumor surveillance, and regulation of autoimmunity and inflammation.^[4] Dysregulation of CD1 presentation has been implicated in diseases like tuberculosis, psoriasis, and asthma, highlighting its therapeutic potential.^[1]

Overview

Discovery and History

The CD1 family of antigen-presenting molecules was first identified in the early 1980s through monoclonal antibodies recognizing surface markers on human thymocytes. In 1980, researchers described a novel antigen, designated T6 or OKT6, expressed on approximately 70% of normal human thymocytes, marking an intermediate stage of T-cell differentiation distinct from major histocompatibility complex (MHC) class I or II molecules. This antigen, later classified as CD1a, was recognized as a non-MHC differentiation marker on immature cortical thymocytes during the First International Workshop on Human Leukocyte Differentiation Antigens in 1982, where it was formally assigned to the CD1 cluster.^[5] Initial studies highlighted its expression on thymic subsets and certain leukemic cells, but its functional role remained unclear, leading to early speculation about peptide presentation similar to MHC molecules.^[6] Key advances in the late 1980s and early 1990s involved molecular cloning that revealed the genetic basis of CD1. In 1986, complementary DNA (cDNA) clones encoding CD1 antigens were isolated, demonstrating that CD1 genes formed a novel family closely related to but distinct from MHC class I genes, located outside the MHC locus on chromosome 1.^[7] This cloning effort identified multiple CD1 genes (CD1A, CD1B, CD1C, and others), confirming their expression primarily on professional antigen-presenting cells like dendritic cells and their structural homology to MHC class I, including association with β2-microglobulin, yet without the polymorphism typical of classical MHC genes.^[8] Early confusion arose from this MHC-like architecture, with hypotheses that CD1 might present peptides, but functional studies began to diverge from this paradigm. The shift to recognizing CD1 as lipid antigen presenters occurred in the mid-1990s through seminal work on T-cell restriction. In 1992, CD1b was shown to restrict the response of human double-negative (CD4− CD8−) αβ T cells to a mycobacterial antigen, marking the first evidence of CD1-mediated antigen presentation independent of MHC. By 1994, this antigen was identified as mycolic acid, a lipid component of Mycobacterium tuberculosis cell walls, confirming CD1's role in presenting glycolipids to T cells and establishing the lipid antigen paradigm.^[9] These findings by Porcelli, Brenner, and colleagues resolved earlier uncertainties, highlighting CD1's specialization for non-peptide antigens. Evolutionarily, CD1 represents a distinct lineage that diverged from classical MHC class I genes early in vertebrate history, likely before the radiation of mammals, with evidence of CD1-like genes in birds suggesting an ancient origin.^[10] While conserved across most mammalian species to survey lipid threats like those from pathogens, CD1 genes are notably absent in certain rodents, such as rats and mice, which lack group 1 CD1 isoforms (CD1a–c) but retain a divergent CD1d.^[11] This evolutionary pattern underscores CD1's adaptation for lipid immunity in species facing diverse microbial exposures, separate from the peptide-focused MHC system.^[12]

General Function in Immunity

CD1 molecules are a family of MHC class I-like glycoproteins that specialize in the presentation of non-peptide antigens, including lipids, glycolipids, and lipopeptides derived from pathogens or self-components, to T lymphocytes. Unlike classical MHC molecules, which primarily bind and display peptide antigens in hydrophilic grooves, CD1 proteins utilize hydrophobic binding pockets to accommodate the nonpolar tails of these lipid antigens, thereby enabling the immune system to recognize a diverse array of lipid structures that are integral to microbial cell walls and host membranes. This specialization allows CD1 to bridge the gap between innate and adaptive immunity by facilitating rapid and specific responses to lipid-based threats.^[13]^[14] The primary function of CD1-mediated antigen presentation is the activation of CD1-restricted T cells, which include diverse subsets such as conventional αβ T cells, invariant natural killer T (iNKT) cells, and γδ T cells. Conventional T cells responding to group 1 CD1 molecules (CD1a, CD1b, CD1c) exhibit adaptive-like diversity in their T cell receptors (TCRs), allowing for broad recognition of microbial lipids, while iNKT cells, restricted by CD1d, possess semi-invariant TCRs that confer innate-like responsiveness to both self and foreign glycolipids. γδ T cells, often activated by CD1c, contribute to early immune surveillance with their unconventional TCRs. These interactions trigger T cell proliferation, cytokine production, and cytotoxic activity, amplifying immune responses. Recent lipidomic studies have revealed that CD1 molecules present a diverse array of over 2,000 self-lipids, including sphingolipids and phospholipids, broadening their role in immune surveillance (as of 2023).^[15]^[16]^[17] CD1-restricted T cells play a crucial role in immune surveillance against infectious agents and malignancies by mounting lipid-specific responses that complement peptide-based immunity. For instance, they detect glycolipids from bacteria such as Mycobacterium tuberculosis and fungi, bacterial lipopeptides, and altered self-lipids in tumors and during viral infections, thereby enhancing clearance of pathogens and tumor cells through targeted cytotoxicity and inflammation. This lipid-focused recognition expands the antigenic repertoire of the adaptive immune system, providing protection against threats that evade classical MHC pathways and supporting overall host defense.^[17]^[14]

Molecular Structure

Overall Architecture

CD1 molecules share a conserved three-dimensional structure resembling that of major histocompatibility complex (MHC) class I proteins, consisting of a transmembrane heavy chain non-covalently associated with the light chain β2-microglobulin. The extracellular portion of the heavy chain comprises three domains: the α1-α2 platform, which forms the antigen-binding region, and the Ig-like α3 domain, which interacts with the T cell receptor (TCR) and β2-microglobulin. This MHC class I-like fold positions the α1 and α2 domains atop an eight-stranded antiparallel β-sheet platform, with the α3 domain stabilizing the overall assembly through its association with β2-microglobulin.^[18] A key conserved feature across all CD1 groups is the hydrophobic antigen-binding groove formed by the α1 and α2 helices, which flank the β-sheet floor and create a cleft adapted for accommodating lipid antigens rather than peptides. This groove is deeper and more enclosed than in classical MHC class I molecules, enabling the capture and presentation of hydrophobic lipids while maintaining structural integrity through the non-covalent linkage to β2-microglobulin. The monomorphic nature of CD1 molecules, characterized by limited allelic variation in contrast to the high polymorphism of MHC proteins, ensures consistent antigen presentation across individuals within a species.^[18]^[19] The first crystal structure of a CD1 molecule, that of mouse CD1d1 at 2.8 Å resolution, was resolved in 1997, revealing the MHC-like fold and the large hydrophobic binding groove. Subsequent structures of human isoforms followed: CD1a in complex with sulfatide at 2.15 Å in 2003, CD1b with a bacterial lipid at 2.8 Å in 2003, human CD1d with α-galactosylceramide at 3.0 Å in 2005, and CD1c with a mycobacterial lipid at 2.5 Å in 2010. Recent structural reviews, including those from 2024, have confirmed these conserved architectural elements while highlighting subtle groove variations that underpin isoform-specific functions without altering the overall scaffold.^[20]^[21]^[22]^[18]

Lipid Binding Grooves and Specificity

The lipid-binding grooves of CD1 molecules, which share a conserved MHC class I-like α1-α2 platform domain, exhibit isoform-specific variations in anatomy that dictate the insertion and accommodation of lipid antigens. CD1a and CD1d feature relatively closed grooves with limited portals, restricting access to smaller lipids and preventing the entry of extended alkyl chains, as evidenced by their compact cleft volumes of approximately 1,350 Å³ for CD1a and 1,650 Å³ for CD1d. In contrast, CD1b and CD1c possess open-ended portals, particularly at the F' and T' pockets, enabling the insertion of longer hydrocarbon tails; CD1b's exceptionally large groove volume of about 2,200 Å³ and its solvent-exposed T' tunnel facilitate binding of bulky, elongated lipids, while CD1c's open F' groove (volume approximately 1,780 Å³) allows conformational flexibility for varied ligand orientations.^[23]^[24] These structural differences underpin the antigen specificity profiles of each CD1 isoform, enabling selective presentation of diverse lipids to T cells. CD1a preferentially binds small, compact lipopeptides such as dideoxymycobactin from Mycobacterium tuberculosis, where the ligand's single alkyl chain fits snugly within the closed groove without protruding extensively. CD1b accommodates long-chain mycobacterial lipids, including mycolic acids and glucose monomycolates, which extend through the open T' portal to span the expansive cleft. CD1c targets phospholipids and glycolipids with moderate chain lengths, leveraging its variable F' pocket to stabilize polar head groups exposed to solvent. CD1d, with its closed but moderately sized groove, presents glycosphingolipids like α-galactosylceramide, where the carbohydrate head projects upward for T cell recognition while acyl chains anchor internally.^[25]^[26]^[23]^[24] CD1e serves as a unique intracellular accessory molecule with chaperone-like functions, facilitating lipid editing, transfer, and exchange within endosomal compartments to optimize antigen loading onto other CD1 isoforms. Its groove, characterized by a wide, water-exposed cleft, loosely binds lipids and promotes their extraction from donor membranes or displacement from stable CD1b complexes, enhancing the diversity of presented antigens without direct surface presentation. Structural analysis reveals that CD1e's shallow binding site supports transient interactions, enabling it to act as a lipid shuttle for CD1b and CD1c.^[27]^[1] Recent cryo-EM structures from 2024-2025 have illuminated the dynamic flexibility of CD1 grooves, particularly in CD1b, where ternary complexes with trehalose monomycolate (TMM) and T cell receptors demonstrate adaptive conformational changes in the antigen-binding site to accommodate diverse microbial lipids and facilitate TCR docking. These high-resolution insights reveal how groove portals undergo localized opening and closing, driven by lipid chain interactions, to broaden antigen selectivity beyond static models.^[28]^[29]

Classification and Isoforms

Human CD1 Molecules

The human CD1 genes are clustered on chromosome 1q23.1 and encode five distinct isoforms: CD1A, CD1B, CD1C, CD1D, and CD1E. These isoforms are classified into three functional groups based on sequence homology and roles in lipid antigen presentation: Group 1 (CD1a, CD1b, and CD1c), which primarily presents microbial lipid antigens to diverse T cell populations; Group 2 (CD1d), which presents lipids to invariant natural killer T (iNKT) cells; and Group 3 (CD1e), which acts as an intracellular chaperone without direct antigen presentation to T cells.^[30]^[31]^[23] Expression of human CD1 molecules is predominantly restricted to professional antigen-presenting cells, including dendritic cells (DCs), B cells, and certain epithelial cells, with notable tissue-specific patterns. For instance, CD1a is highly expressed on Langerhans cells in the skin, while CD1b and CD1c are found on monocyte-derived DCs and subsets of migrating lymph node DCs; CD1d shows broader constitutive expression across hematopoietic and non-hematopoietic cells, such as intestinal epithelial cells. These patterns enable localized immune surveillance, with inducible upregulation in response to inflammatory signals in myeloid cells.^[32]^[33]^[34] Functionally, Group 1 CD1 molecules (CD1a-c) survey exogenous microbial lipids, such as those from mycobacteria, to activate polyclonal T cells with adaptive-like responses, contributing to anti-infective immunity. In contrast, CD1d specializes in presenting endogenous and microbial glycolipids to iNKT cells, which bridge innate and adaptive immunity through rapid cytokine release. CD1e, unique among the isoforms, facilitates lipid antigen loading and editing within endosomal compartments but does not traffic to the cell surface for T cell recognition.^[33]^[35]^[23] Polymorphisms in human CD1 genes are relatively rare but have been associated with altered disease susceptibility, particularly in autoimmune conditions. For example, specific CD1A alleles, such as those influencing expression levels, correlate with increased risk of multiple sclerosis and other inflammatory disorders by modulating lipid presentation efficiency. Similar variants in CD1E have been linked to polygenic contributions in autoimmunity, though their functional impacts remain under investigation.^[36]^[37]^[38]

CD1 in Non-Human Mammals

In mice, the CD1 family is limited to two functional CD1d genes, CD1d1 and CD1d2, both belonging to group 2, with no orthologs of group 1 CD1 molecules (CD1a, CD1b, CD1c) or CD1e due to a genomic deletion event.^[39] CD1d1 is the primary functional isoform, capable of presenting glycolipids to invariant natural killer T (iNKT) cells, while CD1d2 has minimal expression and function.^[23] This restricted repertoire makes mice a valuable model for studying iNKT cell-mediated immunity but limits their utility for investigating group 1 CD1-restricted responses to microbial lipids, such as those from mycobacteria.^[35] Rats similarly lack group 1 CD1 molecules, possessing only a conserved CD1d ortholog akin to that in mice, which underscores the absence of classic CD1 isoforms in muroid rodents.^[40] In contrast, bovines exhibit a markedly expanded CD1 repertoire, with the locus containing 12 genes including two CD1a (group 1), three CD1b (group 1), one CD1e (group 3), and four CD1d (group 2) genes, the latter exhibiting surface expression but limited functionality compared to human and murine CD1d.^[41] ^[42] Bovine CD1a and CD1b proteins differ in their lipid-binding grooves, enabling presentation of diverse microbial antigens, and these molecules show high expression in intestinal mucosa and dendritic cells, facilitating pathogen surveillance in the gut.^[42] This expansion likely reflects evolutionary adaptations in ruminants to their microbial-rich digestive environment.^[34] Pigs display a diverse CD1 gene cluster spanning over 470 kb, encompassing at least 16 genes including CD1a, CD1b, CD1c, CD1d, and CD1e, which closely mirrors the human configuration with both group 1 and group 2 isoforms.^[43] Porcine CD1 expression occurs on dendritic cells and other antigen-presenting cells, supporting broad lipid antigen presentation similar to humans.^[44] These interspecies variations—such as the rodent-specific loss of group 1 CD1 and ruminant expansions—highlight evolutionary divergences that complicate direct translation of human CD1 research to animal models.^[45] These differences have significant implications for preclinical studies, as the absence of group 1 CD1 in mice restricts modeling of human microbial lipid responses, while bovine models offer insights into mycobacterial immunity and inform vaccine design against ruminant pathogens like tuberculosis.^[46] In humans, group 1 CD1 molecules primarily handle exogenous lipids, a function partially recapitulated in pigs and bovines but not rodents.^[23]

Antigen Presentation Mechanisms

Lipid Antigen Loading

Lipid antigen loading onto CD1 molecules occurs through distinct intracellular pathways that enable the capture and editing of lipids into their binding grooves, preparing them for presentation to T cells. For CD1a, loading primarily occurs via recycling from the plasma membrane through early endosomes, allowing capture of endogenous and exogenous lipids without deep lysosomal involvement.^[47] For CD1b and CD1c, the primary route involves endosomal recycling, where these molecules traffic through early and late endosomes to lysosomes, facilitating the loading of exogenous microbial lipids under acidic conditions.^[47] This pathway is mediated by saposins, a family of lipid transfer proteins that solubilize lipids from membranes and promote their insertion into CD1 grooves; for instance, saposin C is crucial for loading complex microbial lipids onto CD1b.^[48] In contrast, CD1d primarily utilizes a de novo loading pathway in the endoplasmic reticulum (ER), where self-lipids are incorporated during biosynthesis, although endosomal exchange can occur for certain antigens.^[47] Chaperone proteins play essential roles in these processes to enhance lipid exchange efficiency. CD1e, a non-polymorphic CD1 family member restricted to endolysosomal compartments, facilitates the editing and transfer of lipids onto CD1b and CD1c by stabilizing partially loaded complexes and aiding in the removal of placeholder self-lipids.^[48] For CD1d, the microsomal triglyceride transfer protein (MTP) acts in the ER to lipidate the molecule with endogenous lipids, ensuring stability and surface expression; inhibition of MTP reduces CD1d-mediated presentation.^[47] These chaperones hijack components of cellular lipid metabolism, allowing CD1 to compete for antigens in crowded membrane environments.^[48] Antigen sources for loading are categorized as exogenous or endogenous, reflecting the diverse origins of lipids presented by CD1. Exogenous lipids, such as bacterial mycolic acids from Mycobacterium tuberculosis, are acquired via phagocytosis and loaded onto CD1b in lysosomes, where their long alkyl chains fit the deep grooves after saposin-mediated extraction. Endogenous lipids, including glycosphingolipids like glucosylceramide, are typically loaded onto CD1d in the ER or exchanged in endosomes, contributing to the recognition of self or altered-self states.^[47] Recent advances have illuminated how lysosomal lipid transfer proteins optimize loading efficiency, with studies mapping CD1 lipidomes revealing size-dependent mechanisms that segregate short- and long-chain antigens into distinct compartments for CD1b.^[49] For example, 2023-2024 analyses demonstrate that lysosomal proteins like NPC2 and saposins enhance the transfer of microbial lipids, increasing presentation potency in vitro.^[48]

T Cell Receptor Interactions

T cell receptors (TCRs) recognize lipid antigens presented by CD1 molecules through docking modes that position the TCR to contact both the CD1 platform and the protruding lipid headgroup. For invariant natural killer T (iNKT) cells, which express a semi-invariant TCR with the Vα24-Jα18 α-chain in humans, docking occurs in a conserved tilted and parallel orientation atop the F' portal of CD1d, allowing the invariant α-chain complementarity-determining region (CDR) loops to engage the lipid headgroup while the diverse β-chain interacts with the CD1d α-helices.^[50] This topology is exemplified by the CD1d-α-galactosylceramide (α-GalCer) complex, a prototypical model where the TCR α-chain CDR3α directly contacts the α-GalCer sugar headgroup, enabling specific recognition of this microbial-derived glycolipid.^[51] In contrast, TCRs recognizing group 1 CD1 molecules (CD1a, CD1b, CD1c) exhibit more diverse docking footprints, often involving polyclonal αβ TCR repertoires that contact the CD1 α1-α2 platform and variable lipid moieties without a single invariant chain.^[52] Recent structural studies, including cryo-electron microscopy (cryo-EM) analyses, have illuminated the molecular contacts in these interactions. For instance, the 2024 cryo-EM structure of the Y-50 TCR bound to CD1b presenting trehalose monomycolate (TMM), a mycobacterial lipid, reveals a ternary complex where the TCR CDR3 loops form a positively charged "cationic cup" that cradles the exposed trehalose headgroup, while the TCR Vβ domain grips the CD1b helices, highlighting lipid headgroup protrusion as key for recognition.^[53] Similarly, X-ray crystallography of iNKT TCR-CD1d-α-GalCer complexes (PDB: 3VWJ) confirms that the lipid headgroup is fully exposed above the CD1d cleft, facilitating TCR surveillance without deep insertion into the binding groove, a feature conserved across CD1 isoforms but adapted for diverse lipid shapes in group 1 molecules.^[50] These contacts underscore a dual recognition mechanism, where TCR affinity is tuned by both CD1 germline elements and lipid variability, enabling broad yet specific immune responses.^[50] Engagement of CD1-lipid-TCR complexes triggers T cell signaling through co-stimulatory pathways, leading to rapid activation and effector functions. In iNKT cells, TCR ligation by CD1d-α-GalCer induces downstream signaling via the CD3 complex, resulting in swift cytokine release, including interferon-γ (IFN-γ) for pro-inflammatory responses and interleukin-4 (IL-4) for Th2 skewing, often within hours of stimulation.^[4] This biphasic cytokine profile amplifies innate and adaptive immunity, with IFN-γ promoting macrophage activation and IL-4 supporting B cell help. For group 1 CD1-restricted T cells, which engage polyclonal repertoires, signaling similarly drives cytokine production and proliferation, but with broader antigen specificity that allows responses to diverse self and microbial lipids, enhancing surveillance against infections like tuberculosis.^[52]

Physiological and Pathological Roles

Roles in Adaptive and Innate Immunity

CD1 molecules play a pivotal role in bridging innate and adaptive immunity through the activation of invariant natural killer T (iNKT) cells, which exhibit innate-like properties despite being part of the adaptive immune system. Upon recognition of lipid antigens presented by CD1d, iNKT cells rapidly produce cytokines such as IFN-γ, IL-4, and TNF-α within hours of stimulation, mimicking the swift response of innate immune cells like NK cells and providing early immunomodulatory signals that enhance dendritic cell maturation and NK cell cytotoxicity.^[54] This rapid activation allows iNKT cells to orchestrate immediate protective responses during infections, such as those caused by bacteria or viruses, before conventional T cells fully engage.^[55] In adaptive immunity, CD1-restricted T cells, including those specific to group 1 CD1 molecules (CD1a–c), expand and form memory populations that confer long-term protection against lipid antigens from pathogens. For instance, CD1b-restricted T cells recognizing mycolic acids from Mycobacterium tuberculosis proliferate during active infection and persist as memory cells capable of mounting robust secondary responses, contributing to infection control and vaccine-induced immunity.^[56] These memory T cells exhibit enhanced effector functions upon re-exposure, such as cytokine production and cytotoxicity, highlighting CD1's role in generating antigen-specific adaptive memory distinct from peptide-MHC pathways.^[57] CD1 expression patterns enable tissue-specific immune surveillance, particularly in mucosal and barrier sites. In the lung and gut, CD1b and CD1c on dendritic cells and macrophages facilitate the presentation of microbial lipids to T cells, supporting ongoing surveillance against pathogens and maintaining homeostasis by modulating local inflammatory responses.^[1] Similarly, CD1a on epidermal Langerhans cells in the skin detects breaches in barrier integrity by presenting self-lipids like wax esters and foreign allergens, activating resident T cells to promote rapid barrier repair and antimicrobial defense.^[58] The balance between tolerance and autoreactivity in iNKT cell development is maintained through recognition of self-lipids presented by CD1d in the thymus. Self-antigens such as iGb3 and phospholipids drive positive selection of iNKT cells, ensuring a diverse repertoire while inhibitory mechanisms, including low-affinity interactions and regulatory cytokines, prevent excessive autoreactivity under steady-state conditions to avoid autoimmunity.^[59] This self-lipid education shapes iNKT functionality, allowing poised responses to foreign threats without compromising self-tolerance.^[60]

Involvement in Diseases

CD1 molecules play critical roles in the pathogenesis of various infectious diseases by facilitating lipid antigen presentation to T cells. In mycobacterial infections, such as tuberculosis caused by Mycobacterium tuberculosis (Mtb), CD1b-restricted T cells recognize mycobacterial lipids like mycolic acids, leading to activation and IFN-γ production that enhances bacterial clearance.^[61] Vaccination strategies targeting these CD1b-presented lipids, such as mycolic acid-loaded nanoparticles, induce potent CD1b-restricted T cell responses and partial protection against Mtb challenge in animal models.^[62] Diet-induced dyslipidemia has been shown to amplify IFN-γ responses from mycolic acid-specific T cells, promoting in vitro mycobacterial killing.^[63] Viruses employ evasion tactics by downregulating CD1d expression on antigen-presenting cells, thereby impairing invariant natural killer T (iNKT) cell activation and innate immune responses. For instance, herpes simplex virus 1 (HSV-1) rapidly suppresses CD1d surface expression through mechanisms involving the US3 kinase and UL56 protein, which promote protein degradation via proteasomal and lysosomal pathways, allowing viral persistence.^[64]^[65] Similarly, human papillomavirus (HPV) and Kaposi's sarcoma-associated herpesvirus (KSHV) downregulate CD1d to evade CD1d-restricted T cell surveillance.^[66]^[67] HIV-1 transmitted founder strains vary in their capacity to downregulate CD1d on dendritic cells, influencing early iNKT cell recognition during infection.^[68] In autoimmune disorders, CD1 molecules contribute to dysregulated T cell responses against self-lipids. CD1a-restricted T cells in the skin promote inflammation in psoriasis and atopic dermatitis by recognizing endogenous lipids, such as those derived from skin phospholipids, leading to cytokine release and tissue damage.^[69]^[70] These T cells amplify Th17 and Th2 responses, exacerbating barrier dysfunction in these conditions.^[71] In systemic lupus erythematosus (SLE), CD1d-restricted iNKT cells exhibit reduced frequency and impaired function, failing to regulate autoreactive B cells and contributing to disease progression; CD1d deficiency in mouse models worsens lupus nephritis through unchecked autoantibody production.^[72]^[73] Invariant NKT cells normally limit activation of CD1d-positive autoreactive B cells, and their dysfunction in SLE correlates with increased autoimmunity.^[74] CD1d-mediated iNKT cell responses are implicated in cancer, where they can target tumors expressing CD1d. iNKT cells directly kill CD1d-positive tumor cells, such as in leukemia and glioblastoma, through recognition of glycolipid-loaded CD1d, releasing cytokines that activate broader antitumor immunity.^[75]^[76] High CD1d expression on tumor cells predicts susceptibility to iNKT-mediated cytotoxicity, and strategies enhancing CD1d-iNKT interactions, like α-galactosylceramide loading, boost tumor control in gastric cancer models.^[77]^[78] Recent insights highlight the role of unconventional CD1-restricted T cells, including iNKT and other lipid-reactive subsets, in solid tumors; these cells exhibit rapid activation kinetics and infiltrate tumors to modulate suppressive microenvironments, though evasion mechanisms limit their efficacy.^[79]^[80] Mucosal CD1 expression influences allergic and infectious diseases at barrier sites. Inhaled allergens upregulate CD1c on pulmonary dendritic cells, enhancing lipid antigen presentation and contributing to Th2-skewed inflammation in asthma.^[81] CD1-mediated responses in mucosal tissues, including the lung and gut, regulate immunity against infections and allergens, with dysregulation linked to exacerbated allergic inflammation.^[1]

Clinical Applications

Diagnostic Uses

CD1 molecules serve as biomarkers in clinical diagnostics by assessing their expression on antigen-presenting cells (APCs) and the frequency of CD1-restricted T cell populations, providing insights into immune dysregulation in various diseases. Flow cytometry and enzyme-linked immunosorbent assay (ELISA) techniques are commonly employed to quantify CD1 expression on APCs such as dendritic cells, enabling evaluation of immune status in conditions like HIV infection. For instance, low counts of CD1c+ myeloid dendritic cells, measured via flow cytometry, correlate with rapid disease progression in early HIV-1 infection, reflecting impaired APC function and higher viral loads. Similarly, HIV-1 infection downregulates CD1c and CD1d expression on APCs through Vpu-dependent mechanisms, detectable by flow cytometry, which serves as a marker of persistent immune activation despite antiretroviral therapy. Lipid-specific tetramers, particularly CD1d loaded with α-galactosylceramide (α-GalCer), facilitate the precise quantification of invariant natural killer T (iNKT) cells in peripheral blood, aiding in the monitoring of immune responses in cancer and infections. These tetramers, developed in the early 2000s, allow for the direct detection and tracking of iNKT cells, which play regulatory roles in antitumor immunity and viral clearance. In hepatocellular carcinoma, flow cytometry using CD1d-PBS57 tetramers reveals altered iNKT cell infiltration in tumor tissues, correlating with disease progression and serving as a prognostic indicator. For viral infections, such as HIV and Mycobacterium tuberculosis, tetramer-based assays quantify iNKT cell frequencies to assess antiviral and antibacterial immunity, with reduced iNKT numbers indicating susceptibility to chronic infection. Disease-specific correlations further highlight CD1's diagnostic utility. In type 1 diabetes, reduced CD1d expression on APCs and lower iNKT cell numbers, quantifiable via CD1d tetramers, are associated with autoimmune β-cell destruction, potentially serving as early biomarkers of disease risk in at-risk individuals. In inflammatory skin conditions like dermatitis, skin biopsies showing increased CD1a+ cells, identified through immunohistochemistry, indicate active epidermal inflammation; for example, higher CD1a+ dendritic cell density in acute atopic dermatitis lesions distinguishes it from chronic phases and aids in differential diagnosis from other dermatoses. Recent advances include the exploration of CD1-restricted responses in tuberculosis diagnostics, where CD1b expression on APCs is modulated by Mycobacterium tuberculosis infection, detectable in lung and spleen tissues via flow cytometry, supporting the development of lipid antigen-based assays for active disease detection. Integrating CD1 profiling with lipidomics in multiplex platforms holds promise for enhancing tuberculosis biomarker panels, as demonstrated in studies identifying CD1b-restricted T cells reactive to mycobacterial lipids.

Therapeutic Potential

The therapeutic potential of targeting CD1 molecules lies in harnessing or modulating lipid antigen presentation to enhance immune responses against infections and cancers, or to suppress aberrant T cell activity in autoimmune conditions. Invariant natural killer T (iNKT) cell agonists, such as analogs of α-galactosylceramide (α-GalCer), have shown promise in cancer immunotherapy by activating iNKT cells via CD1d presentation, leading to rapid cytokine release and tumor cell killing. For instance, α-GalCer-loaded dendritic cells have been tested in clinical trials for melanoma, demonstrating safety and transient iNKT expansion, though efficacy has been limited by anergy induction; optimized analogs like α-GalCer variants aim to mitigate this by sustaining activation without exhaustion.^[82]^[83]^[84] In inflammatory skin diseases, blocking CD1a-mediated T cell responses offers a targeted approach to inhibit autoreactive lipid-specific T cells that drive pathogenesis in psoriasis. Anti-CD1a antibodies have suppressed IL-17 and IL-22 production from CD1a-reactive T cells in humanized mouse models of psoriasis, reducing skin inflammation without broad immunosuppression. A phase 1 clinical trial of an anti-CD1a monoclonal antibody (NCT04668066) is evaluating safety in atopic dermatitis, with preclinical data suggesting applicability to psoriasis through selective T cell inhibition. While small-molecule CD1a ligands like farnesol modulate responses, antibody-based blockade remains the primary strategy in recent reviews.^[85]^[86]^[87] CD1-restricted presentation of lipid antigens has informed vaccine development for tuberculosis (TB) and HIV, where mycobacterial lipids like lipoarabinomannan elicit protective T cell responses. Incorporating CD1-presented lipids as adjuvants in subunit vaccines enhances CD1b- and CD1d-restricted immunity, as shown in human trials where lipid-loaded nanoparticles induced polyfunctional T cells against Mycobacterium tuberculosis. Bovine models, which express orthologous CD1 molecules capable of presenting mycobacterial lipids, have validated vaccine efficacy against bovine TB, providing translational insights for human formulations by demonstrating reduced lung pathology upon lipid antigen challenge. Similar strategies for HIV target CD1d-presented glycosphingolipids to boost mucosal immunity.^[88]^[89]^[90] Emerging advances include chimeric antigen receptor (CAR)-engineered iNKT cells that recognize CD1d-presented tumor lipids, showing enhanced infiltration and cytotoxicity in solid tumors as of 2025 preclinical data. However, challenges persist due to tumor evasion mechanisms, such as CD1d downregulation or lipid remodeling to avoid iNKT recognition, which dampens therapeutic responses; strategies like CD1d upregulation via epigenetic modifiers are under investigation to overcome this.^[91]^[92]^[93]

References

[1]
CD1-mediated immune responses in mucosal tissues - Nature
Sep 11, 2023 · CD1s are constitutively expressed by professional and nonprofessional antigen-presenting cells in mucosal tissues, namely, the skin, lung, and intestine.
[2]
CD1 antigen presentation: how it works | Nature Reviews Immunology
The CD1 molecules bind and present amphipathic lipid antigens for recognition by T-cell receptors. Here, we outline the recent advances in our understanding.
[3]
THE CD1 SYSTEM: Antigen-Presenting Molecules for T Cell ...
Apr 1, 1999 · CD1 proteins are conserved in all mammalian species so far examined and are prominently expressed on cells involved in antigen presentation, ...
[4]
Structure and function of the CD1 family of MHC-like cell surface ...
The CD1 family of proteins are structurally related to MHC class I proteins, but are only distantly related to the class I proteins or other MHC-linked class I ...
[5]
The clusters of differentiation (CD) defined by the First ... - PubMed
The clusters of differentiation (CD) defined by the First International Workshop on Human Leucocyte Differentiation Antigens. Hum Immunol. 1984 Sep ...Missing: CD1 | Show results with:CD1
[6]
The heterogeneity and functional capacities of human thymocyte ...
... Boumsell, J Dausset, and A BernardAuthors Info & Affiliations. August 1, 1984 ... (CD1, CD3-CD5, CD8) revealed a high degree of phenotypic heterogeneity. Six ...
[7]
A novel family of human major histocompatibility complex ... - Nature
Oct 9, 1986 · A molecular genetic approach is needed to investigate the CD1 system, to clarify its relationship to TL antigens and to understand its ...
[8]
Isolation of CD1 genes: a family of major histocompatibility ... - PNAS
A cloned cDNA has been used to identify CD1 genes in a human genomic library. Five CD1 genes have been isolated, and Southern blot analysis suggests that these ...
[9]
Recognition of a lipid antigen by CD1-restricted αβ+ T cells | Nature
Dec 15, 1994 · Atypical sideways recognition of CD1a by autoreactive γδ T cell receptors ... Boumsell, L. in Leukocyte Typing IV (eds Knapp, W. et al.) 251–269 ...
[10]
Evolutionary biology of CD1 - PubMed
Most evidence indicates that CD1 probably evolved from a classical MHC class I (MHC I) gene at some point during vertebrate evolution.
[11]
an evidence for different evolutionary histories between classic CD1 ...
In contrast to the absence of the classic CD1 genes in rats and mice, the entire region of nonpolymorphic CD1D gene has been conserved through mammalian ...
[12]
Evolutionary origin and diversification of the mammalian CD1 ...
Phylogenetic analysis of mammalian CD1 DNA sequences revealed that these genes are more closely related to the class I major histocompatibility complex (MHC) ...
[13]
https://doi.org/10.1146/annurev.immunol.22.012703.104608
[14]
https://doi.org/10.1038/nri3889
[15]
https://doi.org/10.1146/annurev-immunol-032414-112334
[16]
https://doi.org/10.1016/j.molimm.2024.03.011
[17]
https://doi.org/10.1016/j.cell.2023.08.022
[18]
T Cell Receptors Recognize CD1 Molecules
Jun 27, 2024 · Namely, CD1 molecules bind and display lipid-based Ags to T cells. These lipid-reactive T cells are also emerging as key players in protective ...
[19]
CD1: From Molecules to Diseases - PMC - NIH
Oct 31, 2017 · The non-polymorphic nature of CD1 genes creates a situation in which nearly all humans express CD1 proteins with the same sequence and structure ...Missing: monomorphic allelic variation
[20]
Crystal structure of CD1a in complex with a sulfatide self antigen at a ...
Here we report the crystal structure of human CD1a in complex with a sulfatide self antigen at a resolution of 2.15 A. The lipid adopts an S-shaped conformationMissing: date | Show results with:date
[21]
The crystal structure of human CD1d with and without ... - PubMed
Here we report the crystal structure of human CD1d in complex with synthetic alpha-galactosylceramide at a resolution of 3.0 A.
[22]
The 2.5 Å structure of CD1c in complex with a mycobacterial lipid ...
Here we present the crystal structure of CD1c at 2.5 Å resolution, in complex with the pathogenic Mycobacterium tuberculosis antigen mannosyl-β1- ...
[23]
Mechanisms and Consequences of Antigen Presentation by CD1
The CD1 proteins are a family of non-polymorphic, MHC class I-related molecules that present lipid antigens to subsets of T lymphocytes with innate- or adaptive ...
[24]
Discovery of deoxyceramides and diacylglycerols as CD1b scaffold ...
Zippered CD1 molecules consist of zipper-encoding regions (αZip and βZip) at the C termini of heavy chains and human β2m sequences, which are linked by ...
[25]
Crystal structure of human CD1e reveals a groove suited for lipid ...
Jul 25, 2011 · The 16-Å-wide aperture in CD1e is halfway between those in CD1 and MHC class I and class II molecules (18–20 Å in the middle of the cleft) (12).
[26]
A conserved human CD4+ T cell subset recognizing the ...
Mar 17, 2025 · A cryo-electron microscopy study of CD1b-TMM-TCR complexes revealed unique antigen recognition by conserved features of TCRs, positively ...
[27]
8ZOX: 3D structure of Y-50 TCR-TMM-CD1b ternary complex
Jan 1, 2025 · A cryo-electron microscopy study of CD1b-TMM-TCR complexes revealed unique antigen recognition by conserved features of TCRs, positively ...
[28]
Human CD1a-deficiency is Common and Genetically Regulated - NIH
Despite their structural homology to MHC Class I heavy chain genes, CD1 genes exhibit limited allelic diversity as a result of non-synonymous polymorphisms. In ...Missing: monomorphic | Show results with:monomorphic<|control11|><|separator|>
[29]
The intricacies of self-lipid antigen presentation by CD1b
... CD1b compared to the other members of Group 1 CD1s. To date, 11 crystal structures of human CD1b have been deposited onto the Protein Data Bank (PDB) ...<|control11|><|separator|>
[30]
CD1-mediated immune responses in mucosal tissues - NIH
Sep 11, 2023 · First, in the skin, CD1a is highly expressed on Langerhans cells and slightly expressed on Langerin (CD207)- CD14+ DCs. CD1b-d are expressed on ...
[31]
The versatility of the CD1 lipid antigen presentation pathway
Feb 20, 2018 · CD1 molecules prove highly versatile in lipid presentation and play a role in a number of disease conditions, employing diverse mechanisms to elicit a variety ...Autoimmunity And Allergy · Cd1 Structure · Cd1 Localization<|control11|><|separator|>
[32]
Mammalian CD1 and MR1 genes | Immunogenetics
Jul 28, 2016 · Expression patterns of CD1 isoforms. Human cortical thymocytes express high levels of CD1a, CD1b, CD1c, and CD1d on their cell surface. Broad ...Mammalian Cd1 And Mr1 Genes · Cd1 Loci In Less Well... · Mammalian Mr1 Genes
[33]
Role of Group 1 CD1-Restricted T Cells in Infectious ... - Frontiers
CD1c molecules have a unique antigen-binding mode that allows for presentation of diverse antigens, such as highly branched lipid species to T cells (57).
[34]
CD1A and CD1E gene polymorphisms are associated ... - PubMed
CD1A and CD1E polymorphisms contribute to the polygenic susceptibility to MS. The functional effects of CD1 polymorphisms are unknown.
[35]
The Role of CD1 Gene Polymorphism in the Genetic Susceptibility to ...
Jan 20, 2023 · Some research showed a relationship between CD1 polymorphisms and some autoimmune and inflammatory diseases.
[36]
Association between genetic variants in CD1A and CD1D genes ...
Mounting evidence revealed a link between CD1 polymorphisms and certain autoimmune and inflammatory diseases including inflammatory neuropathies (12) ...
[37]
Diverse antigen presentation by the Group 1 CD1 molecule, CD1c
Nov 3, 2012 · The structures of CD1a and CD1b differ in the size and length of their lipid antigen pockets; CD1a has a very short A' pocket which was ...
[38]
Structural organization of rat CD1 typifies evolutionarily conserved ...
In contrast to the complete absence of the classic CD1 in rats and mice, the entire region of nonpolymorphic CD1D has been conserved through mammalian evolution ...
[39]
Expression Patterns of Bovine CD1 In Vivo and Assessment of ... - NIH
Mar 27, 2015 · In cattle, two CD1A and three CD1B genes are transcribed. The proteins encoded by these genes differ in their antigen binding domains and in ...
[40]
The bovine CD1 family contains group 1 CD1 proteins, but no ...
In this study, we describe the CD1 family of genes in cattle (Bos taurus) and provide evidence that B. taurus expresses CD1a, CD1e, and multiple CD1b molecules.Missing: mammals | Show results with:mammals
[41]
Analysis of the genomic structure of the porcine CD1 gene cluster
We identified 16 genes in this region and newly identified CD1A2, CD1B, CD1C, CD1D, and CD1E. Porcine CD1 genes were located in clusters between KIRREL and ...
[42]
CD1− and CD1+ porcine blood dendritic cells are enriched for the ...
Jan 20, 2017 · Two functionally specialised populations, termed cDC1 and cDC2, have been described in humans, mice, ruminants and recently in pigs. Pigs are an ...
[43]
the evolutionary history of CD1 genes and the NKR-P1/ligand systems
Jul 25, 2016 · The discovery of only a single CD1 molecule in the genomes of the bandicoot, the Tasmanian devil and the green anole suggests that the ...
[44]
The bovine CD1 family contains group 1 CD1 proteins, but no ...
Jan 1, 2006 · Cattle can be used as a model to study group 1 CD1-restricted T cell immunity, including its role in the defense against mycobacterial ...Missing: mammals | Show results with:mammals
[45]
Four Pathways of CD1 Antigen Presentation to T cells - PMC - NIH
Jul 28, 2017 · The closed ends on MHC I restrict binding to nonamer peptides, whereas the open-ended groove of MHC II binds longer peptides with ragged ends.
[46]
https://research.birmingham.ac.uk/en/publications/the-bovine-cd1-family-contains-group-1-cd1-proteins-but-no-functi/
[47]
Insights into the CD1 lipidome - Frontiers
Aug 21, 2024 · We performed a comprehensive lipidomic analysis of soluble CD1 molecules. We identified 1040 lipids, of which 293 were present in all isoforms.
[48]
https://www.jlr.org/article/S0022-2275(20)33048-0/fulltext
[49]
The Molecular Basis for Recognition of CD1d/α-Galactosylceramide ...
We know how most Natural Killer T (NKT) cells react with this unusual ligand because they use a single invariant T cell receptor (TCR) alpha chain to do the job ...
[50]
Role of Group 1 CD1-restricted T Cells in Host Defense and ...
Group 1 CD1-restricted T cells are members of the unconventional T cell family that recognize lipid antigens presented by CD1a, CD1b, and CD1c molecules.
[51]
A conserved human CD4 + T cell subset recognizing the ... - JCI
Dec 24, 2024 · Our cryo-EM structure provides direct evidence for the presence of an antigen-independent “patch” by which TRBV4-1-encoded residues interact ...
[52]
Functions of CD1d-Restricted Invariant Natural Killer T Cells in ...
Upon TCR stimulation by glycolipid antigens, iNKT cells rapidly produce large amounts of cytokines, including interferon-γ (IFNγ) and interleukin-4 (IL-4).
[53]
Invariant natural killer T cells: bridging innate and adaptive immunity
Activated iNKT cells produce several cytokines with the capacity to jump-start and modulate an adaptive immune response. A variety of glycolipid antigens that ...
[54]
Innate iNKT cells: from biological insight to clinical impact - Frontiers
This review focuses on CD1d-restricted iNKT cells. Activation of iNKT cells ... Further, they combine features of both innate and adaptive immunity ...
[55]
A mycolic acid–specific CD1-restricted T cell population ... - JCI
Group 1 CD1–restricted T cells recognize mycobacterial lipids, but their function in human TB is unclear and their ability to establish memory is unknown. Here, ...
[56]
The T-Cell Response to Lipid Antigens of Mycobacterium ... - Frontiers
MA-related lipids are presented only by CD1b as this is the only CD1 molecule with an open T′ pocket allowing the insertion of long fatty acids. A second family ...
[57]
CD1a and skin T cells: a pathway for therapeutic intervention - PMC
Therefore, CD1a is well placed to act as a sentinel to detect breaches in barrier integrity and may be a key driver of associated pathology. Beyond the skin, ...
[58]
iNKT cell autoreactivity: what is “self” and how is it recognized? - PMC
iNKT cells recognize and are activated by diverse glycolipid antigens, many of which are found in microorganisms. However, iNKT cells also demonstrate some ...
[59]
Strategy of lipid recognition by invariant natural killer T cells: 'one for ...
Jun 1, 2012 · Given that all CD1d–lipid–TCR interactions seemingly occur in an almost identical structural pattern, how can this be reconciled with findings ...Inkt Cell Lipid Antigens · Role Of The Tcr-β Chain · Do Inkt Tcr Binding...
[60]
Mycolic acid-specific T cells protect against Mycobacterium ...
Dec 10, 2015 · Our findings highlight the vaccination potential of targeting group 1 CD1-restricted lipid-specific T cells against Mtb infection.
[61]
Vaccination with mycobacterial lipid loaded nanoparticle leads to ...
Oct 25, 2023 · Mycolic acid (MA), a major lipid component of the Mtb cell wall, is presented by human CD1b molecules to unconventional T cell subsets. These MA ...
[62]
Diet-induced dyslipidemia enhances IFN-γ production in mycolic ...
May 3, 2025 · We found that diet-induced dyslipidemia led to increased IFN-γ production by MA-specific T cells, which promoted mycobacterial clearance in vitro.
[63]
Herpes Simplex Virus 1 US3 Phosphorylates Cellular KIF3A To ...
We and others previously reported that, upon infection, HSV-1 rapidly and efficiently downregulates CD1d cell surface expression and suppresses the function of ...
[64]
HSV-1 UL56 protein recruits cellular NEDD4-family ubiquitin ligases ...
Apr 15, 2025 · A leaky late gene, UL56, most efficiently suppresses CD1d expression by degrading the protein, apparently via both proteasome- and lysosome-dependent pathways.
[65]
CD1d, a sentinel molecule bridging innate and adaptive immunity, is ...
CD1d downregulation is utilized by a variety of microbes to evade immune detection. We demonstrate here that CD1d is downregulated in human papillomavirus (HPV)- ...
[66]
Regulation of CD1d expression and function by a herpesvirus infection
KSHV modulation of CD1d expression represents a strategy for viral evasion of innate host immune responses and implicates CD1d-restricted T cells as regulators ...
[67]
Innate Invariant NKT Cell Recognition of HIV-1-Infected Dendritic ...
Transmitted founder viral isolates differed in their CD1d downregulation capacity, suggesting that diverse strains may be differentially ...
[68]
CD1a and skin T cells: a pathway for therapeutic intervention
Apr 23, 2024 · In this review, we overview the structure and role of CD1a and outline the current evidence implicating CD1a in the development of psoriasis, atopic dermatitis ...Missing: barrier 2023
[69]
Current Understanding of the Roles of CD1a-Restricted T Cells in ...
May 31, 2021 · CD1a-restricted T cells contribute to inflammatory skin disorders, including atopic dermatitis, psoriasis, allergic contact dermatitis, and wasp/bee venom ...<|separator|>
[70]
CD1a and bound lipids drive T-cell responses in human skin disease
Aug 11, 2023 · We review studies showing that skin-derived αβ T cells directly recognize CD1a proteins, and certain bound lipids, such as contact dermatitis allergens, ...Missing: atopic | Show results with:atopic
[71]
The role of iNKT cells in the immunopathology of systemic lupus ...
The reduced frequency of iNKT cells in peripheral blood of lupus patients supports the idea of a protective role for these cells in the immunopathology of SLE.
[72]
Immunoregulatory role of CD1d in the hydrocarbon oil-induced ...
In this study, we show that CD1d deficiency exacerbates lupus nephritis induced by the hydrocarbon oil pristane. This exacerbation in disease is associated with ...
[73]
Invariant NKT cells limit activation of autoreactive CD1d-positive B ...
May 10, 2010 · Faulty activation of autoreactive B cells is a hallmark of autoimmune diseases like systemic lupus erythematosus (SLE).
[74]
Activated invariant natural killer T cells directly recognize leukemia ...
iNKT cells show direct cytotoxicity toward CD1d-positive tumor cells, especially when CD1d presents glycolipid antigens. However, iNKT cell recognition of CD1d- ...
[75]
CD1d expression in glioblastoma is a promising target for NKT cell ...
Oct 31, 2020 · To address if iNKT cells can target glioblastoma to exert anti-tumor activity, we assessed the expression of CD1d, an antigen-presenting molecule for iNKT ...
[76]
CD1d expression level in tumor cells is an important determinant for ...
The high expression level of CD1d may be a predictor whether the tumor is a good target of iNKT cells.
[77]
Utilization of invariant natural killer T cells for gastric cancer treatment
iNKT cells have potent in vivo and in vitro anti-tumor activities against CD1d-positve gastric cancer in the presence of α-galactosylceramide. Cisplatin could ...<|separator|>
[78]
Unconventional T cells in anti-cancer immunity - PubMed
Jul 17, 2025 · This review further depicts the distinct kinetics of responses, highlighting a rapid activation of unconventional T cells in solid versus ...<|separator|>
[79]
TCR-engineered iNKT cells induce robust antitumor response by ...
Aug 12, 2022 · TCR-iNKT cells achieved robust cancer control by simultaneously modulating intratumoral suppressive myeloid populations and killing malignant cells.
[80]
Tolerogenic Signaling by Pulmonary CD1c+ Dendritic Cells Induces ...
Jul 19, 2014 · Impaired respiratory immunity is linked to the enhanced susceptibility to infections. ... Exposure of lung CD1c(+) DCs from nonobstructed subjects ...
[81]
Inhaled allergen-driven CD1c up-regulation and enhanced antigen ...
Objective: To investigate the influence of hRTDC on the balance between atopy and allergic asthma in human subjects and to determine whether CD1 expression by ...Missing: lung infections
[82]
α-GalCer and iNKT Cell-Based Cancer Immunotherapy - NIH
Jun 6, 2019 · The prototype ligand of iNKT cells, α-galactosylceramide (α-GalCer) has been used in over 30 anti-tumor clinical trials with mostly suboptimal outcomes.
[83]
(PDF) α-GalCer and iNKT Cell-Based Cancer Immunotherapy
Aug 6, 2025 · GalCer demonstrated potent anti-tumor activity against metastatic B16 melanoma cells (7,8). Furthermore, α-GalCer demonstrated synergistic anti- ...
[84]
The Current Landscape of NKT Cell Immunotherapy and the Hills ...
Almost all clinical trials examining iNKT cell immunotherapy have used α-GalCer (KRN7000) to stimulate iNKT cells; however, there is a growing list of ...
[85]
CD1a and skin T cells: a pathway for therapeutic intervention
The CD1a subtype is highly and continuously expressed within the skin, most notably on Langerhans cells, and has been demonstrated to present self and foreign ...
[86]
CD1a and skin T cells – a pathway for therapeutic intervention
Jan 4, 2024 · In this review, we overview the structure and role of CD1a ... skin barrier dysfunction, immune response dysregulation, and skin dysbiosis.
[87]
https://www.nature.com/articles/ni.3497
[88]
CD1 and mycobacterial lipids activate human T cells - PMC
CD1 proteins and mycobacterial lipids form specific targets of human T cells, and T-cell receptors (TCRs) recognize CD1-lipid complexes.
[89]
CD1-restricted T cells: are unconventional allies the key to future TB ...
Although most mammals possess group 1 CD1 genes, muroid rodents (mice and rats) are an exception (109–112). Thus, guinea pigs, which express CD1b and CD1c, have ...<|control11|><|separator|>
[90]
Establishment of CD1b-restricted immunity to lipid antigens in the ...
Cells and lipids were incubated overnight to allow for lipid cellular trafficking and lipid presentation in the context of CD1b. These target cells were then ...
[91]
CAR-NKT cell therapy: a new promising paradigm of cancer ...
May 8, 2023 · NKT cells have multiple features that make them potent cells against tumors and would be a powerful replacement for T cells and natural killer (NK) cells.
[92]
Unconventional T cells in anti-cancer immunity - Frontiers
Unconventional T cells respond to non-peptidic metabolite antigens presented by MHC class I-like proteins, such as CD1 and MHC-related protein 1 (MR1).CD1-restricted T cells in cancer · The γδ T cells in cancer · Therapeutic potential of...
[93]
Optimizing iNKT-driven immune responses against cancer by ...
This review discusses all the possible ways of cancer immune evasion and restoration of immune responses mediated by CD1d-iNKT interactions.